Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
08:00am, Sunday, 30'th Mar 2025
NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such i
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
10:00am, Friday, 28'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
06:00pm, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
10:00am, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
08:00pm, Wednesday, 26'th Mar 2025
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such inve
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation
10:00am, Wednesday, 26'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
10:00am, Tuesday, 25'th Mar 2025
NEW YORK , March 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
03:00pm, Monday, 24'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect
10:00am, Monday, 24'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
09:25am, Monday, 24'th Mar 2025
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
10:00am, Sunday, 23'rd Mar 2025
NEW YORK CITY, NY / ACCESS Newswire / March 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such inves
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
09:30am, Sunday, 23'rd Mar 2025
Things are going from bad to worse for Sarepta Therapeutics (SRPT 0.84%), a biotech focusing on gene therapies. The company's performance over the past six months had already been unimpressive.
